HK1068811A1 - Substituted oxazolidinones for combinational therapy - Google Patents

Substituted oxazolidinones for combinational therapy

Info

Publication number
HK1068811A1
HK1068811A1 HK05101508.8A HK05101508A HK1068811A1 HK 1068811 A1 HK1068811 A1 HK 1068811A1 HK 05101508 A HK05101508 A HK 05101508A HK 1068811 A1 HK1068811 A1 HK 1068811A1
Authority
HK
Hong Kong
Prior art keywords
substituted oxazolidinones
combinational therapy
oxazolidinones
combinations
combinational
Prior art date
Application number
HK05101508.8A
Other languages
English (en)
Inventor
Alexander Straub
Thomas Lampe
Josef Pernerstorfer
Elisabeth Perzborn
Jens Pohlmann
Susanne Roehrig
Karl-Heinz Schlemmer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7688824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1068811(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of HK1068811A1 publication Critical patent/HK1068811A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HK05101508.8A 2001-06-20 2005-02-23 Substituted oxazolidinones for combinational therapy HK1068811A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129725A DE10129725A1 (de) 2001-06-20 2001-06-20 Kombinationstherapie substituierter Oxazolidinone
PCT/EP2002/006237 WO2003000256A1 (de) 2001-06-20 2002-06-07 Kombinationstherapie substituierter oxazolidinone

Publications (1)

Publication Number Publication Date
HK1068811A1 true HK1068811A1 (en) 2005-05-06

Family

ID=7688824

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05101508.8A HK1068811A1 (en) 2001-06-20 2005-02-23 Substituted oxazolidinones for combinational therapy

Country Status (33)

Country Link
US (2) US7767702B2 (xx)
EP (1) EP1411932B1 (xx)
JP (1) JP4667744B2 (xx)
KR (1) KR100904138B1 (xx)
CN (1) CN100577162C (xx)
AT (1) ATE457171T1 (xx)
AU (1) AU2002312982B2 (xx)
BG (1) BG66354B1 (xx)
BR (1) BRPI0210941B8 (xx)
CA (1) CA2451258C (xx)
CO (1) CO5550434A2 (xx)
CU (1) CU23366B7 (xx)
CY (1) CY1110019T1 (xx)
CZ (1) CZ303715B6 (xx)
DE (2) DE10129725A1 (xx)
DK (1) DK1411932T3 (xx)
EC (1) ECSP034916A (xx)
EE (1) EE05419B1 (xx)
ES (1) ES2338997T3 (xx)
HK (1) HK1068811A1 (xx)
HR (1) HRP20040042B1 (xx)
HU (1) HU230120B1 (xx)
IL (2) IL159257A0 (xx)
MX (1) MXPA03011519A (xx)
NO (1) NO334821B1 (xx)
NZ (1) NZ530223A (xx)
PL (1) PL206803B1 (xx)
PT (1) PT1411932E (xx)
RU (1) RU2321407C9 (xx)
SI (1) SI1411932T1 (xx)
SK (1) SK287904B6 (xx)
UA (1) UA82986C2 (xx)
WO (1) WO2003000256A1 (xx)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
EP1631560A2 (en) * 2003-04-25 2006-03-08 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
WO2004101552A1 (en) * 2003-05-14 2004-11-25 Orchid Chemicals & Pharmaceuticals Ltd Oxazolidinone derivatives as antibacterial agents
DE10336716A1 (de) 2003-08-11 2005-03-10 Merck Patent Gmbh Verfahren zur Herstellung von N-Aryl-morpholinonen
US7687627B2 (en) * 2003-09-08 2010-03-30 Wockhardt Limited Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy
DE10342570A1 (de) * 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
WO2005027896A1 (ja) * 2003-09-19 2005-03-31 Kissei Pharmaceutical Co., Ltd. 併用医薬
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
US7371743B2 (en) * 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
US7521470B2 (en) 2004-06-18 2009-04-21 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005018690A1 (de) * 2005-04-22 2006-10-26 Bayer Healthcare Ag Imino-oxazolidine und ihre Verwendung
JP5214096B2 (ja) * 2005-06-17 2013-06-19 富士フイルムファインケミカルズ株式会社 新規なビピリジン誘導体
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
PL1934208T3 (pl) * 2005-10-04 2011-09-30 Bayer Ip Gmbh Nowa polimorficzna postać 5-chloro-N-({ (5S)-2-okso-3-[4-( 3-okso-4-morfolinylo)-fenylo]-1,3-oksazolidyn-5-ylo}-metylo)-2-tiofenokarboksamidu
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047564A1 (de) * 2005-10-04 2007-05-31 Bayer Healthcare Ag Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
DE102005052174A1 (de) 2005-11-02 2007-06-06 Bayer Healthcare Ag Phenylen-bis-oxazolidin-Derivate und ihre Verwendung
US7700590B2 (en) 2006-02-09 2010-04-20 University Of New Orleans Research And Technology Foundation, Inc. Antibacterial agents
DE102006007146A1 (de) * 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
JP5227311B2 (ja) * 2006-05-05 2013-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US7998992B2 (en) * 2007-03-30 2011-08-16 Institute Of Medicinal Molecular Design, Inc. Oxazolidinone derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1
KR101009594B1 (ko) * 2007-05-09 2011-01-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미딘을 가지는 ＦＸａ 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물
WO2008140220A1 (en) * 2007-05-09 2008-11-20 Legochem Bioscience Ltd. Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
DE102007028320A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
WO2009023233A1 (en) 2007-08-14 2009-02-19 Concert Pharmaceuticals, Inc. Substituted oxazolidinone derivatives
JP2011506363A (ja) * 2007-12-11 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全の処置および／または予防用のオキサゾリジノン類
KR100898361B1 (ko) * 2008-07-03 2009-05-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
WO2011012321A1 (en) 2009-07-31 2011-02-03 Krka, D.D., Novo Mesto Processes for crystallization of rivaroxaban
CN102050819B (zh) * 2009-11-10 2012-05-23 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
JP5796872B2 (ja) * 2009-12-17 2015-10-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の結晶性塩
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
CN107021932A (zh) * 2010-06-29 2017-08-08 欧美嘉股份有限公司 制备5‑左旋‑氨甲基‑3‑芳基‑2‑恶唑烷酮类的方法
CA2810478A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited Processes for the preparation of 4-{4-[5(s)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one
CN104693139B (zh) * 2011-01-07 2017-04-19 浙江九洲药业股份有限公司 一种合成利伐沙班中间体的新工艺
MD4557C1 (ro) * 2011-05-06 2018-10-31 Egis Gyogysszegyar Nyilvanosan Mukodo Reszvenytarsasag Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu
EP2753619A2 (en) * 2011-09-08 2014-07-16 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
EP2766373B1 (en) * 2011-10-11 2016-08-17 Council of Scientific & Industrial Research Sila analogs of oxazolidinone derivatives and synthesis thereof
WO2014096214A1 (en) 2012-12-21 2014-06-26 Farma Grs, D.O.O. A process for preparation of rivaroxaban
EP2897619A4 (en) * 2012-12-26 2016-08-17 Wanbury Ltd ALDEHYDE DERIVATIVE FROM SUBSTITUTED OXAZOLIDINONES
CN103936763B (zh) * 2013-01-18 2017-10-31 中国科学院上海药物研究所 噁唑烷酮类化合物及其制备方法和用途
WO2015124995A1 (en) 2014-02-19 2015-08-27 Aurobindo Pharma Ltd Solid dosage forms of rivaroxaban
KR101968190B1 (ko) * 2014-10-30 2019-04-11 청두 바이위 파머수티컬 씨오., 엘티디 징코라이드 B(Ginkgolide B)와 Ⅹa 인자 억제제를 포함한 약물 조성물 및 그 제조방법과 용도
CN104356124A (zh) * 2014-10-30 2015-02-18 广东东阳光药业有限公司 噁唑烷酮类化合物及其组合物和用途
CN104402876A (zh) * 2014-11-25 2015-03-11 沈阳药科大学 噁唑烷酮类化合物及其应用
CN104447728B (zh) * 2014-12-05 2017-01-04 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104447729A (zh) * 2014-12-05 2015-03-25 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104478866B (zh) * 2014-12-05 2017-07-07 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104497008B (zh) * 2014-12-09 2016-11-16 广东东阳光药业有限公司 取代噁唑烷酮类化合物及其使用方法和用途
ES2885437T3 (es) 2015-03-03 2021-12-13 Saniona As Formulación de combinación de tesofensina y metoprolol
US10828310B2 (en) 2018-02-02 2020-11-10 Bayer Pharma Aktiengesellschaft Reducing the risk of cardiovascular events
CA3090439A1 (en) * 2018-02-06 2019-08-15 Shanghai Haihe Pharmaceutical Co., Ltd. Compound having bet inhibitory activity and preparation method and use therefor
US11608320B2 (en) 2020-02-02 2023-03-21 Kuwait University Oxazolidinone hydroxamic acid derivatives
CN111253383A (zh) * 2020-03-27 2020-06-09 南京国星生物技术研究院有限公司 一种利伐沙班的合成方法
CN112159402B (zh) * 2020-10-28 2022-04-05 南京法恩化学有限公司 一种利伐沙班的制备方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2811555A (en) 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ES8506659A1 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
EP0316594B1 (en) 1987-10-21 1993-09-29 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5654285A (en) * 1991-04-06 1997-08-05 Astra Pharmaceuticals Limited ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation
DE69216251T2 (de) 1991-11-01 1997-05-15 Upjohn Co Substituierte aryl- und heteroaryl-phenyloxazolidinone
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
ES2134870T3 (es) * 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
JPH10513446A (ja) 1995-02-03 1998-12-22 ファルマシア・アンド・アップジョン・カンパニー ヘテロ芳香族環置換フェニルオキサゾリジノン抗微生物剤
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
KR100463772B1 (ko) 1995-09-01 2005-11-09 파마시아 앤드 업존 캄파니 엘엘씨 4내지8원헤테로사이클릭환에탄소-탄소결합을갖는페닐옥사졸리디논
AU6964096A (en) 1995-09-15 1997-04-01 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
CA2240946C (en) 1995-12-21 2002-09-10 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor xa inhibitors
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
JPH1081632A (ja) * 1996-07-15 1998-03-31 Sankyo Co Ltd 医 薬
CA2261040C (en) * 1996-07-15 2009-01-20 Sankyo Company, Limited Pharmaceutical composition comprising combination useful for treatment or prevention of arteriosclerosis or xanthoma
WO1998011896A1 (en) 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
AU737995B2 (en) 1997-05-30 2001-09-06 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
EP0994874A1 (en) 1997-07-11 2000-04-26 PHARMACIA & UPJOHN COMPANY Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
NZ504503A (en) 1997-11-12 2002-10-25 Upjohn Co Oxazolidinone derivatives and pharmaceutical use as antimicrobial agents
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
DE19802239A1 (de) 1998-01-22 1999-07-29 Bayer Ag Neue mit Bicyclen substituierte Oxazolidinone
CN1288462A (zh) 1998-01-23 2001-03-21 法玛西雅厄普约翰美国公司 噁唑烷酮组合库、组合物和制备方法
WO1999037304A1 (en) 1998-01-27 1999-07-29 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
PL344049A1 (en) 1998-05-18 2001-09-24 Upjohn Co Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
EA200100966A1 (ru) * 1999-03-11 2002-02-28 Дюпон Фармасьютикалз Компани ЛЕЧЕНИЕ ТРОМБОЗА КОМБИНИРОВАННЫМ ПРИМЕНЕНИЕМ ИНГИБИТОРА ФАКТОРА Xa И АСПИРИНА, АКТИВАТОРА ТКАНЕВОГО ПЛАЗМИНОГЕНА (TPA), АНТАГОНИСТА GPIIB/IIIA, НИЗКОМОЛЕКУЛЯРНОГО ГЕПАРИНА ИЛИ ГЕПАРИНА
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
NZ519725A (en) 1999-12-21 2004-05-28 Upjohn Co Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AU2225901A (en) 1999-12-28 2001-07-09 Ajinomoto Co., Inc. Aspartame derivative crystals
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
PL1934208T3 (pl) 2005-10-04 2011-09-30 Bayer Ip Gmbh Nowa polimorficzna postać 5-chloro-N-({ (5S)-2-okso-3-[4-( 3-okso-4-morfolinylo)-fenylo]-1,3-oksazolidyn-5-ylo}-metylo)-2-tiofenokarboksamidu
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
DE102008028071A1 (de) * 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure

Also Published As

Publication number Publication date
HUP0400240A2 (hu) 2004-08-30
MXPA03011519A (es) 2004-10-28
BRPI0210941B1 (pt) 2015-09-15
HRP20040042A2 (en) 2005-04-30
ECSP034916A (es) 2004-02-26
IL159257A (en) 2010-02-17
HRP20040042B1 (hr) 2014-04-25
NZ530223A (en) 2005-07-29
BR0210941A (pt) 2004-06-08
ES2338997T3 (es) 2010-05-14
CN100577162C (zh) 2010-01-06
NO334821B1 (no) 2014-06-10
ATE457171T1 (de) 2010-02-15
NO20035743D0 (no) 2003-12-19
DK1411932T3 (da) 2010-05-31
EE200400020A (et) 2004-04-15
JP2004534083A (ja) 2004-11-11
CZ303715B6 (cs) 2013-04-03
CZ20033451A3 (en) 2004-03-17
HUP0400240A3 (en) 2006-02-28
RU2321407C2 (ru) 2008-04-10
AU2002312982B2 (en) 2008-01-24
WO2003000256A1 (de) 2003-01-03
PL368079A1 (en) 2005-03-21
DE10129725A1 (de) 2003-01-02
CO5550434A2 (es) 2005-08-31
DE50214206D1 (de) 2010-03-25
CU23366B7 (es) 2009-04-14
KR20040020058A (ko) 2004-03-06
EP1411932B1 (de) 2010-02-10
SI1411932T1 (sl) 2010-05-31
NO20035743L (no) 2004-02-17
US7767702B2 (en) 2010-08-03
RU2321407C9 (ru) 2009-03-27
US20040242660A1 (en) 2004-12-02
CA2451258C (en) 2011-01-18
SK15302003A3 (sk) 2004-07-07
US20100267685A1 (en) 2010-10-21
CA2451258A1 (en) 2003-01-03
IL159257A0 (en) 2004-06-01
HU230120B1 (hu) 2015-08-28
BRPI0210941B8 (pt) 2021-05-25
JP4667744B2 (ja) 2011-04-13
UA82986C2 (uk) 2008-06-10
WO2003000256A9 (de) 2003-02-06
PT1411932E (pt) 2010-04-01
PL206803B1 (pl) 2010-09-30
KR100904138B1 (ko) 2009-06-24
EE05419B1 (et) 2011-06-15
CY1110019T1 (el) 2015-01-14
RU2004101404A (ru) 2005-06-10
BG108443A (en) 2005-03-31
CN1523986A (zh) 2004-08-25
EP1411932A1 (de) 2004-04-28
BG66354B1 (bg) 2013-09-30
SK287904B6 (sk) 2012-03-02

Similar Documents

Publication Publication Date Title
HK1068811A1 (en) Substituted oxazolidinones for combinational therapy
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
AP2088A (en) Phenethanolamine derivatives for treatment of respiratory diseases
MXPA04002405A (es) Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
GB0001309D0 (en) Valve arrangement
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
FI956014A (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
MY144616A (en) Substituted dihydroquinazolines
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
TW200510449A (en) Acylated nonadepsipeptides
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
MXPA05014184A (es) Utilizacion de acido hialuronico para la preparacion de composiciones para el tratamiento de aftas en la cavidad oral.
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
SE0004101D0 (sv) New use
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
AU2002254930A1 (en) Novel medicament compositions based on anticholinergic agents and endothelin antagonists
AU2002214030A1 (en) Novel medicament compositions consisting of tiotropium salts and antihistamines for treating respiratory illnesses
WO2003029221A8 (de) Tetrahydroisochinoline, ihre herstellung und verwendung als schmerzmittel
GR20010100390A (el) Χρηση του diclofenac h αποδεκτων αλατων αυτου για την αντιμετωπιση των εγκαυματων.
WO2002072527A3 (de) 1-butansäurederivate wie z.b. carbomethoxypropionylcyanid oder leflunomidderivate und deren therapeutische anwendung
LT2002105A (en) Novel use of siberian fir oil

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220606